Posts
Bets on Generative AI to Redefine Drug Discovery
The landscape of drug discovery is on the brink of transformation, thanks to innovations in generative AI. IntelliGenAI’s IntelliFold foundation model is setting new benchmarks in structural biology, achieving results that rival or even surpass the renowned AlphaFold 3. This technology not only promises to enhance the efficiency of drug development but also introduces controllable features that could significantly improve the success rates of new therapies.
Historically, the drug development process has been plagued by the infamous double ten rule, which dictates a decade-long timeline, exorbitant costs, and a dismal success rate of less than 10%. However, with the emergence of startups like IntelliGenAI, there is a palpable sense of optimism. By harnessing the power of generative AI, they aim to streamline the drug discovery process, making it faster and more cost-effective. Their recent angel funding round, reportedly in the tens of millions, underscores the confidence investors have in this groundbreaking approach.
As we look ahead, the question remains: will generative AI truly revolutionize the pharmaceutical industry, or will it face the same challenges that have historically hindered progress? The potential is immense, and the journey is just beginning.
Original source: https://pandaily.com/bets-on-generative-ai-to-redefine-drug-discovery-intelli-gen-ai-and-their-foundation-model-approach